Decades of drug development experience from AstraZeneca, Merck, Wyeth and world-leading universities, bringing first-in-class biased modulators from bench to bedside.
Over 25 years of international experience in biotech spanning drug discovery, development, and investment. Former CEO of Vesper Bio, advancing programs from discovery to Phase II. Previously Operating Partner at the Lundbeck Foundation. PhD Organic Chemistry, Cardiff. Fellow of the Royal Society of Chemistry.
Professor of Physiology at Stockholm University. 25 years of experience in pharmacology and physiology. 60+ scientific publications, 20+ patent applications. Entrepreneur and founder of several companies. The scientific visionary behind GRK2-biased agonism.
Extensive clinical background with 20 years in global drug development at AstraZeneca. Led the global development of dapagliflozin (Forxiga), now AstraZeneca's largest brand. Collaborated with Harvard and Stanford. MD, PhD from Gothenburg University. 200+ publications including 4 in NEJM.
Nearly 25 years of experience in business development within small and mid-sized companies. Extensive background as CFO and CEO across multiple industries. Trained economist with deep competence in financial management, business analysis, and value creation.
PhD in Infectious Disease Control. 24 years of experience in life science research with 15 years of industrial experience in drug development. Experience from several pharma collaborations. 30+ scientific publications.
PhD in Neuroscience. 20+ years of life science research experience. Unique knowledge of Atrogi's mechanism of action. Proven leader of high-performance research teams. 20+ scientific publications.
Over 20 years of experience in drug discovery and development in pharmaceutical companies. Strong background in medicinal chemistry. Inventor of AZD-3293 (beta-secretase inhibitor for Alzheimer's). Author of 19 publications. PhD in Organic Synthesis, Stockholm University.
Extensive preclinical background with over 8 years of life science research and strategy experience. Leads preclinical strategy and business development at Atrogi, driving drug discovery for obesity, diabetes, and rare diseases. Global scientific foundation spanning the University of Hong Kong, Karolinska University Hospital, and Stockholm University. PhD in Molecular Physiology from Stockholm University. 15+ scientific publications.
35 years of experience from various positions in large pharmaceutical companies and small biotech companies, including serving as the first CEO of Atrogi. Extensive experience from international pharmaceutical collaborations. Now retired, he runs a consulting company specializing in medicinal chemistry and intellectual property. PhD in organic chemistry, followed by postdoctoral research in the field. He is an author of more than 25 scientific publications and an inventor on more than 70 patent applications.
PhD in Biochemistry with more than 20 years of research experience spanning physiology, biochemistry, and pharmaceutical drug development. Author of more than 20 scientific publications.
PhD in molecular Biology and Signaling with 20 + years of experience in research and preclinical laboratory work, with multiple scientific papers as a result. With strong attention to details and the ability to integrate insights from multiple fields. I'm highly dedicated to find the solution from single molecule to cell signaling and through whole-body metabolism.
MSc in Molecular Biology with a background in physiology and experience in both in vitro and in vivo research. Contributes to the planning and management of preclinical studies and broader research and development activities.
Background in clinical and regulated environments with experience supporting cross-functional projects and company operations.
Board certified MD and DDS, Karolinska Institutet. Former EVP Global Medicines Development , AstraZeneca Plc and CEO AstraZeneca AB, Sweden. Chairman of Atrogi AB and Xspray Pharma AB. Non-executive director Flerie AB and Mereo Biopharmna Group Plc.
Professor of Physiology at Stockholm University. 25 years in pharmacology. 60+ publications, 20+ patents. Entrepreneur and founder of several companies.
MD, Weill Cornell Medical College. Advanced Management Program, Harvard Business School. Former President Global R&D at Wyeth. Former Executive Director at Merck Research Laboratories. Gastroenterologist, Stanford.
MD and PhD in Cell and Molecular Biology, Lund University. Former Medical Director at Swedish Orphan Biovitrum. CEO and Founder of Cormorant Pharmaceuticals. CEO of Sixera Pharma.
PhD in Physical Chemistry from Stockholm University. Post-doc at FMP Berlin
Venture Partner at Flerie CEO at Empros Pharma Senior project manager at the Royal Academy of Engineering Sciences Project manager at Sidec Technologies.
Board member at Prokarium and AnaCardio
